Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine
| Autor: | Farhana Islam, Victoria S. Marshe, Sidney H. Kennedy, Eric J. Lenze, Jane A. Foster, Jordan F. Karp, Benoit H. Mulsant, Daniel M. Blumberger, James L. Kennedy, Gustavo Turecki, Malgorzata Maciukiewicz, Volodymyr Yerko, Daniel J. Müller, Laura M. Fiori, Jennie Yang, Charles F. Reynolds |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Treatment response Venlafaxine Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine microRNA medicine Humans Biological Psychiatry Depression (differential diagnoses) Aged Pharmacology Depression business.industry Venlafaxine Hydrochloride Middle Aged Late life depression Antidepressive Agents 030227 psychiatry MicroRNAs Treatment Outcome Sample size determination Antidepressive Agents Second-Generation Antidepressant Female business Biomarkers Pharmacogenetics medicine.drug |
| Zdroj: | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 100:109867 |
| ISSN: | 0278-5846 |
| Popis: | Background MicroRNAs (miRNAs) are small 22 nucleotides long, non-coding RNAs that are potential biomarkers for antidepressant treatment response. We aimed to replicate previous associations of miRNAs with antidepressant treatment response in a sample of older adults diagnosed with late-life depression. Methods Our sample included 184 older adults diagnosed with moderately severe depression that received open-label venlafaxine (up to 300 mg/day) for approximately 12 weeks. We quantified miRNA expression levels at baseline and week 12 for miRNAs miR-1202, miR-135a-5p, miR-16-5p, miR-146a-5p, miR-146b-5p, miR-425-3p, and miR-24-3p to explore their association with remission status, response trajectories, and time-to-remission. Results At T0 and T12, there were no differences in miRNA expression levels between remitters and non-remitters. However, remitters showed a trend toward higher baseline miR-135a-5p (Median = 11.3 [9.9, 15.7], p = .083). Prior to correction, baseline miR-135a-5p expression levels showed an association with remission status (OR = 1.8 [1.0, 3.3], p = .037). Individuals with higher baseline miR-135a-5p showed better response trajectories (F = 4.5, FDR-corrected p = 4.4 × 10−4), particularly at weeks 10 and 12 (p Limitations Although the sample size was relatively modest, our findings are consistent with the literature suggesting that higher miR-135a-5p levels may be associated with better antidepressant treatment response. Conclusions However, the miRNA signature of antidepressant response in older adults may be different as compared to younger adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect